NCT03940833: Phase 1/2: Adoptive BCMA CAR-NK Cells - RRMM
Updated: May 26, 2022
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.
Asclepius Technology Company Group (Suzhou) Co., Ltd.
Department of Hematology, Wuxi People's Hospital, Nanjing Medical University
Wuxi, Jiangsu, China, 214000
BCMA CAR-NK 92 cells
ClinicalTrials.gov Identifier: NCT03940833
First Posted : May 7, 2019
allogeneic natural killer cell line NK-92